Featured Clinical Leader Editorial

  1. Siteless DCTs Are Real … And Happening Now 6/20/2024

    Siteless DCTs (decentralized trials) are rare, but Praxis Precision Medicines is running one now for patients with essential tremor (ET). Marcio Souza, PharmD, the company’s president and CEO, talks about why they chose this model and the surprising speed at which it is progressing.

  2. Take-Home Microdosing Trial Studies Sub-Hallucinogenic For Depression 4/30/2024

    MindBio Therapeutics CEO Justin Hanka details the company’s Phase 2a clinical trial investigating the use of a take-home microdosing regimen for depression.

  3. Will Today's Clinical Trial Trends Become Tomorrow's Routine? 4/23/2024

    Clinical trial trends can be divided into two groups — those related to changes in the conduct of clinical trials and those related to the changes in therapeutic areas. Will these trends hold steady as 2024 unfolds?

  4. Post-Pandemic Planning: Using Direct-To-Patient Deliveries For Supply Chain Management 2/23/2024

    UCB Vice President – Head of Global Clinical Science and Operations Tero Laulajainen gets us up to speed on direct-to-patient (DTP) trials and how UCB is leveraging it today.

  5. 4 Things I Learned At SCOPE 2024 2/21/2024

    The Summit for Clinical Ops Executives (SCOPE) ran from Feb. 11-4. Discover four things Executive Editor Abby Proch learned at the annual event.

  6. Ramblings From A First-Time SCOPE Attendee 2/15/2024

    Dan Schell, chief editor of Clinical Leader, discusses what sessions stood out to him and some of the KOLs he rubbed elbows with while attending his first SCOPE Summit. 

  7. 4 Things I'm Looking Forward To At SCOPE 2024 2/1/2024

    The Summit for Clinical Ops Executives (SCOPE) begins Feb. 11. Discover four things Executive Editor Abby Proch is looking forward to at the annual event.

  8. 3 Ways Biotechs Can Lower The Cost Of Clinical Trials 1/23/2024

    LongeVC has identified three innovative models to help biotechs lower the cost of their clinical trials.

  9. Clinical Trial Diversity, Flexibility Championed By The Food And Drug Omnibus Reform Act 5/23/2023

    The Food and Drug Omnibus Reform Act, signed into law by President Biden on Dec. 29, 2022, includes provisions intended to modernize clinical trials and are broadly divided into two categories: encouraging the enrollment of diverse populations and facilitating novel clinical trial designs.

  10. Why Developing A Metrics-Driven Culture Is A Clinical Operations Must-Do 4/14/2023

    The number of systems used to support the conduct of clinical trials has increased and the amount of data used to monitor our portfolio, studies, and processes has soared. While there is still value in using traditional dashboards and reports, the use of advanced analytics and RWD/E is enabling us to ask more sophisticated questions to be more predictive — what will happen — and prescriptive — how to make it happen.